• Mashup Score: 1

    bladder cancer, Bacillus Calmette-Guerin (BCG), BCG treatment, BCG Naïve Non-Muscle Invasive Bladder Cancer, non muscle invasive bladder cancer (NMIBC), KEYNOTE-057trial, Novel Treatment Options for BCG Naïve Non-Muscle Invasive Bladder, Immune Priming, Immune Check Point Inhibitors, KEYNOTE-676 trial, trans urethral resection of bladder tumor (TURBT), Pembrolizumab, Atezolizumab, Durvalumab, metastatic urothelial carcinoma of the bladder, Sasanlimab, POTOMAC study, NCT03504163.

    Tweet Tweets with this article
    • Novel treatment options for BCG naïve nonmuscle-invasive #BladderCancer: immune priming and immune checkpoint inhibitors. #LibraryResource @RKSayyid @UofT and @zklaassen_md @GACancerCenter discuss the current state of the evidence for ongoing trials > https://t.co/zGyYh3Yqwi https://t.co/MkbJ4w4yGl

  • Mashup Score: 1

    urothelial cancer of the bladder, bladder cancer, Bacillus Calmette-Guerin (BCG), BCG treatment, BCG naive non muscle invasive bladder cancer, transurethral resection of bladder tumor (TURBT), Novel Treatment Options for BCG Naïve Non-Muscle Invasive Bladder Cancer, Intravesical Chemotherapy, electromotive mitomycin, CUETO 93009, Hyperthermic Intravesical Chemotherapy (HIVEC), gemcitabine, docetaxel.

    Tweet Tweets with this article
    • Novel treatment options for BCG naïve non-muscle invasive #BladderCancer: intravesical chemotherapy. #LibraryResource @RKSayyid @UofT and @zklaassen_md @GACancerCenter discuss current and emerging evidence for intravesical chemotherapy > https://t.co/WilrVrGlkl https://t.co/HhPOIijpiX

  • Mashup Score: 5

    FDA approval of pembrolizumab for BCG-unresponsive patients with NMIBC, Non-Muscle Invasive Bladder Cancer (NMIBC), BCG-unresponsive Non-Muscle Invasive Bladder Cancer, Immune Checkpoint Inhibitors, Pembrolizumab, KEYNOTE-057 trial, intravenous pembrolizumab.

    Tweet Tweets with this article
    • BCG-unresponsive non-muscle invasive #BladderCancer: Immune checkpoint inhibitors. #LibraryResource @RKSayyid @UofT and @zklaassen_md @GACancerCenter discuss currently available evidence and key ongoing studies > https://t.co/nLQ3sqBqlw https://t.co/gHrVqsEP4N